在5×FAD小鼠中通过NOD1驱动的神经炎症缓解高脂肪饮食加速的阿尔茨海默氏症
Ming Wang1, Baoyuan Jin2,3, Jia Xu4
1Health Science Center, Ningbo University, Ningbo 315211, China.
Nutrients
|August 28, 2025
概括
艾文胺-C (Avn-C) 改善记忆力并减少阿尔茨海默氏症
科学领域:
- 神经科学
- 药理学
- 代谢疾病
背景情况:
- 通常由高脂肪饮食 (HFD) 引起的肥胖会加剧阿尔茨海默病 (AD) 的病态.
- 由HFD引起的肥胖会引发神经炎症和中央胰岛素抵抗,从而损害突触功能.
- 在阿尔茨海默氏症模型中,一种来自麦的化合物Avenanthramide-C (Avn-C) 显示出抗炎和神经保护作用.
研究的目的:
- 在肥胖的背景下,研究Avn-C改善AD特征的机制.
- 探索Avn-C对饮食诱导的肥胖AD小鼠的神经炎症和突触功能的影响.
主要方法:
- 由HFD诱导的肥胖5×FAD小鼠接受了Avn- C的治疗.
- 评估了认知功能,突触可塑性和结构.
- 评估了神经炎症,并使用激动剂 (C12-iE-DAP) 探测了NOD1通路.
主要成果:
- 治疗Avn-C减少了粉样β (Aβ) 沉积,改善了突触蛋白的表达和可塑性.
- 在空间和识别记忆方面的认知缺陷被Avn-C扭转.
- 抑制了NOD1/ RIP2/ NF- kB信号通路,减少了神经炎症.
结论:
- 通过抑制NOD1/ RIP2/ NF- kB介导的神经炎症,对抗肥胖导致的AD病态.
- 对于与肥胖相关的阿尔茨海默病,Avn-C 是一种潜在的治疗策略.
更多相关视频
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.5K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.9K
相关概念视频
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260